Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
On Oct. 14, 2026, UFPT is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Ufp Technologies Inc is a mid-cap company with a market capitalization of $2.28B. It ranks number 25 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for UFPT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, UFPT included.
Follow UFPT free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
| Metric | UFPT | Rank |
|---|---|---|
| Market Cap | $2.28B | 25/60 |
| P/E Ratio | 31.53x | 8/20 |
| P/B Ratio | 4.93x | 26/55 |
| EPS | $9.25 | – |
| Book Value/Share | $59.70 | – |
| Revenue/Share | $81.55 | – |
| Metric | UFPT | Rank |
|---|---|---|
| ROE | 15.6% | 10/39 |
| ROA | 10.6% | 7/42 |
| ROIC | 16.0% | 11/54 |
| Gross Margin | 28.4% | 51/52 |
| Operating Margin | 15.2% | 13/53 |
| Net Margin | 11.4% | 12/41 |
| EBT Margin | 14.0% | 13/53 |
| Tax Rate | 18.4% | – |
| Metric | UFPT | Rank |
|---|---|---|
| Current Ratio | 3.00x | 36/58 |
| Quick Ratio | 1.72x | 37/54 |
| D/E Ratio | 0.47x | 32/55 |
| Financial Leverage | 1.47x | 32/55 |
| Interest Coverage | 16.4x | 6/48 |
| Working Capital | $157M | 39/58 |
| Metric | UFPT | Rank |
|---|---|---|
| Operating Cash Flow | $72M | 23/54 |
| OCF Growth YoY | -14.1% | 25/32 |
| Metric | UFPT | Rank |
|---|---|---|
| Asset Turnover | 0.93x | 12/51 |
| Receivables Turnover | 5.6x | 35/50 |
| Inventory Turnover | 4.5x | 6/50 |
| Fixed Assets Turnover | 8.2x | 23/51 |
| Days Sales Outstanding | 65 days | 16/50 |
| Days Inventory | 81 days | 45/50 |
| Payables Period | 27 days | 44/45 |
| Cash Conversion Cycle | 120 days | 28/41 |
| Metric | UFPT | Rank |
|---|---|---|
| Total Revenue | $631M | 25/51 |
| Operating Income | $96M | 15/54 |
| Net Income | $72M | 14/42 |
| SG&A Expense | $84M | 45/53 |
| Cost of Goods Sold | $452M | 19/52 |
| Metric | UFPT | Rank |
|---|---|---|
| Shares Outstanding | 8M | – |
| Total Current Assets | $235M | 34.4% of assets |
| Cash & Short-term Investments | $9M | 1.3% of assets |
| Accounts Receivable | $113M | 16.6% of assets |
| Inventory | $100M | 14.7% of assets |
| Total Liabilities | $219M | 32.2% of assets |
| Short-term Debt | $45M | 6.6% of assets |
Companies classified under the same SEC industry code as Ufp Technologies Inc (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| UFPT Ufp Technologies Inc | ▶ | $2.28B |
| SYK Stryker Corp | ▼ | $108.38B |
| MMM 3m Co | ▼ | $83.94B |
| BSX Boston Scientific Corp | ▼ | $62.77B |
| BDX Becton Dickinson & Co | ▼ | $51.04B |
| MDLN Medline Inc. | ▶ | $46.94B |
| RMD Resmed Inc | ▼ | $33.91B |
| DXCM Dexcom Inc | ▶ | $32.42B |
| WST West Pharmaceutical Services Inc | ▼ | $26.17B |
| SOLV Solventum Corp | ▼ | $14.69B |
| BAX Baxter International Inc | ▶ | $12.87B |
| PEN Penumbra Inc | ▼ | $12.61B |
| GMED Globus Medical Inc | ▼ | $10.25B |
| GKOS Glaukos Corp | ▲ | $9.76B |
| PODD Insulet Corp | ▼ | $9.58B |
| STVN Stevanato Group S.P.A. | ▲ | $5.83B |
| HAE Haemonetics Corp | ▼ | $5.54B |
| TFX Teleflex Inc | ▼ | $5.27B |
| MMSI Merit Medical Systems Inc | ▼ | $5.26B |
| MMED Minimed Group, Inc. | ▶ | $5.18B |
| HTFL Heartflow, Inc. | ▲ | $4.38B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.55B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.46B |
| ATRC Atricure, Inc. | ▶ | $2.89B |
| INSP Inspire Medical Systems, Inc. | ▶ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▲ | $1.86B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.67B |
| NVCR Novocure Ltd | ▲ | $1.67B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.61B |
| DRTS Alpha Tau Medical Ltd. | ▲ | $1.26B |
| TNDM Tandem Diabetes Care Inc | ▶ | $1.16B |
| IRMD Iradimed Corp | ▲ | $1.15B |
| BVS Bioventus Inc. | ▶ | $1.14B |
| PRCT Procept Biorobotics Corp | ▲ | $1.09B |
| IART Integra Lifesciences Holdings Corp | ▼ | $1.08B |
| AORT Artivion, Inc. | ▲ | $1.04B |
| SIBN Si-Bone, Inc. | ▲ | $882M |
| SGP Spyglass Pharma, Inc. | ▲ | $800M |
| BBNX Beta Bionics, Inc. | ▲ | $796M |
| MDXG Mimedx Group, Inc. | ▲ | $684M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| SSII Ss Innovations International, Inc. | ▲ | $511M |
| TCMD Tactile Systems Technology Inc | ▶ | $505M |
| BWAY Brainsway Ltd. | ▲ | $467M |
| SGHT Sight Sciences, Inc. | ▲ | $462M |
| CERS Cerus Corp | ▲ | $455M |
| ANGO Angiodynamics Inc | ▲ | $451M |
| NPCE Neuropace Inc | ▶ | $435M |
| RCEL Avita Medical, Inc. | ▲ | $413M |
| CARL Carlsmed, Inc. | ▲ | $395M |
| OFIX Orthofix Medical Inc. | ▼ | $377M |
| EMBC Embecta Corp. | ▲ | $351M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $344M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $299M |
| MOBI Mobia Medical, Inc. | ▲ | $283M |
| ANIK Anika Therapeutics, Inc. | ▲ | $275M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $267M |
| OSUR Orasure Technologies Inc | ▲ | $263M |
| PROF Profound Medical Corp. | ▲ | $256M |
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Justin Ages - CJS Securities, Inc. Good day, and welcome to the UFP Technologies Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would ...
Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity ...
On Oct. 14, 2026, UFPT is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
A per-ticker accuracy statistic for UFPT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Ufp Technologies Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
60 issuers in our coverage, UFPT included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.